Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1773
Title: Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial
Authors: Moon, Daniel
Ruljancich, Paul
Grummet, Jeremy
Crosthwaite, Alan
Peters, Justin
McKenzie, Dean
Other Authors: Bowden, Patrick
See, Andrew
Frydenberg, Mark
Haxhimolla, Hodo
Costello, Anthony
Pranavan, Ganes
So, Kevin
Gwini, Stella
Nolan, Skye
Smyth, Lloyd
Everitt, Craig
Keywords: Stereotactic Body Radiotherapy
SBRT
Oligometastatic Prostate Cancer
PCa
Prostate cancer
Men
Androgen Deprivation Therapy
ADT
Androgen Deprivation Therapy-Free Survival
ADT-FS
Synchronous Oligometastases
Oligometastatic PCa Lesions
Oligometastases
Epworth HealthCare Eastern
Epworth HealthCare
Issue Date: Jun-2019
Publisher: International Union Against Cancer; Wiley
Citation: (2019). Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial. International journal of cancer.
Abstract: Stereotactic body radiotherapy (SBRT) can delay escalation to systemic treatment in men with oligometastatic prostate cancer (PCa). However, large, prospective studies are still required to evaluate the efficacy of this approach in different patient groups. This is the interim analysis of a prospective, single institution study of men relapsing with up to five synchronous lesions following definitive local treatment for primary PCa. Our aim was to determine the proportion of patients not requiring treatment escalation following SBRT. In total, 199 patients were enrolled to receive fractionated SBRT (50 Gray in 10 fractions) to each visible lesion. Fourteen patients were castration resistant at enrolment. The proportion of patients not requiring treatment escalation 2 years following SBRT was 51.7% (95% CI: 44.1-59.3%). The median length of treatment escalation-free survival over the entire follow-up period was 27.1 months (95% CI; 21.8-29.4 months). Prior androgen deprivation therapy (ADT) predicted a significantly lower rate of freedom from treatment escalation at 2 years compared to no prior ADT (odds ratio = 0.21, 95% CI: 0.08-0.54, p = 0.001).
URI: http://hdl.handle.net/11434/1773
DOI: 10.1002/ijc.32509.
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/31199504/
ISSN: 0020-7136
Journal Title: International Journal of Cancer.
Type: Journal Article
Affiliated Organisations: Icon Cancer Centre, Richmond, VIC, Australia.
Department of Surgery, Monash University, Clayton, VIC, Australia
Australian Urology Associates, Melbourne, VIC, Australia
Department of Urology, The Canberra Hospital, Canberra, ACT, Australia
Australian National University, Canberra, ACT, Australia
Department of Surgery, University of Melbourne, Parkville, VIC, Australia
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Department of Medical Oncology, The Canberra Hospital, Canberra, ACT, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, VIC, Australia
School of Public Health and Preventive Medicine, Monash University, Clayton, VIC, Australia
Type of Clinical Study or Trial: Prospective Study
Prospective Clinical Trial
Appears in Collections:Cancer Services
Epworth Prostate Centre

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.